TrialDiabetologia2024

Safety, tolerability and immunogenicity of PRV-101, a multivalent vaccine targeting coxsackie B viruses (CVBs) associated with type 1 diabetes: a double-blind randomised placebo-controlled Phase I trial.

Heikki Hyöty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.